Back to Agenda
Session 4: Clinical Trial Safety Data Evaluation, From Ongoing Monitoring to Risk Characterization
Session Chair(s)
Ranjeeta Sinvhal, MD
Executive Medical Director, Medical Safety, AbbVie, United States
Bethany Van Veen
CEO and Founder, Perspective Pharmacovigilance, United States
Clinical trial pharmacovigilance requires a structured and scientifically robust approach to safety monitoring, signal evaluation, and risk characterization throughout drug development. This session will provide practical perspectives on reviewing and interpreting clinical trial safety data across the development lifecycle, from ongoing blinded studies to post-unblinding benefit-risk assessments. Experts from industry and regulatory backgrounds will discuss best practices for aggregate safety review, evaluation of adverse events of special interest (AESIs), integration of laboratory and clinical data, effective data visualization, and approaches to defining adverse drug reactions (ADRs) and risks for Risk Management Plans (RMPs). Through case examples and panel discussion, attendees will gain practical insights into modern approaches for translating clinical trial safety data into meaningful development and regulatory decisions.
Have an account?